September 12, 2025Open Access

CXCL12 derived from cancer-associated fibroblasts mediates dysfunctional intratumoral adaptive immunity in diabetic pancreatic adenocarcinoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis showed dysfunctional immunity in diabetic pancreatic adenocarcinoma, indicating CAF involvement in immune suppression.

Diabetic pancreatic adenocarcinoma exhibits a dysfunctional immune landscape attributed to CAF-derived cxcl12, impacting treatment outcomes.
The study identified cxcl12's role in transforming immune phenotypes of cd8+ T cells and B cells, highlighting its relevance in diabetes.
Analysis of multiple algorithms revealed significant associations of cxcl12 with immune infiltration in diabetic pancreatic adenocarcinoma patients.
Blocking the cxcl12-cxcr4 pathway with plerixafor demonstrated therapeutic potential in models of diabetic pancreatic cancer.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis showed dysfunctional immunity in diabetic pancreatic adenocarcinoma, indicating CAF involvement in immune suppression.